Clinical Trial

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-23.
Trial Details
NCT Number NCT07221032
Lead Sponsor Medical College of Wisconsin
Conditions Relapse Multiple Myeloma, Refractory Multiple Myeloma
Enrollment 12 participants
Start Date 2026-10
Primary Completion 2028-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-10